SK Bioscience Co Ltd (302440 KO) stock market data APIs
₩52134.458
273(0.5%)
as of September 15, 2025
Try our APIs with
free plan!
SK Bioscience Co Ltd Financial Data Overview
Price chart is built with
Anychart
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
Prev. Close
52134.458
Open
52407.4581
High
52407.4581
Low
51881.4579
52 wk Range
35800-58700
Market Cap
4 067 357 M
Shares Outstanding
78 369 K
Revenue
534 914 M
EPS
-210
Beta
1.215
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with SK Bioscience Co Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SK Bioscience Co Ltd data using free add-ons & libraries
Get SK Bioscience Co Ltd Fundamental Data
SK Bioscience Co Ltd Fundamental data includes:
- Net Revenue: 534 914 M
- EBITDA: -69 195 513 856
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-30
- EPS/Forecast: -199.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SK Bioscience Co Ltd News
New
SK bioscience Expands Influenza Vaccine Exports to Southern Hemisphere Market
750,000 doses of influenza vaccine to be supplied to Southeast Asia and Latin America in the first half of the year. Expanded exports markets ensure year-round vaccine production, enhancing supply sta...
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to ...
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2026. Joint R&D project between SK and CEPI includes ...
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
This approval paves the way for exports to the world's fourth most populous country. SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
